Enosi Life Sciences Announces Executive Appointments as the Company Prepares for Period of Growth

SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) — Enosi Life Sciences, a drug research and development company focused on providing industry-leading therapeutics for inflammatory autoimmune diseases and cancer, announced today its appointment of Jeff Huitt as Chief Financial Officer and Thomas Becker as VP, Investor Relations.

Huitt has served as Principal of Orion Consulting, LLC out of Denver for nearly two decades, advising high growth/high potential companies both public and private on enhancing their value. Huitt’s expertise as a contract executive includes leading finance, accounting, and operations while implementing corporate governance initiatives. Prior to Orion Consulting, Huitt served in multiple consultant and executive roles with companies across technology, oil and gas, and sustainability, providing finance, accounting, and back-office support during periods of startup and high revenue growth.

“I’m thrilled to join Enosi Life Sciences during this exciting period for the company and look forward to working toward achieving our business objectives as the scientific team continues its groundbreaking research,” said Huitt, CFO, Enosi Life Sciences. “Dr. Michael Shepard and Sir Marc Feldmann are the preeminent leaders in their respective fields and have positioned the company on an exciting path forward.”

Thomas Becker has worked for the last 14 years to enhance the investor relations initiatives of seven different OTCBB companies. Prior to his time in IR, Becker worked as a consultant for independent hotel owners, drawing on two decades of hospitality management experience with Hilton Hotel Corp. Becker began working with Enosi Life Sciences in a contractor capacity in October of 2020.

“I’m excited to join Enosi to lead the investor initiatives in a full-time capacity, and to continue working with the great minds at the forefront of this important health issue,” said Becker, VP of Investor Relations, Enosi Life Sciences. “Enosi’s portfolio of immuno-oncology therapeutic candidates has vast potential to both provide more optimal treatment outcomes for patients and generate value for our shareholders.”

“We are pleased to add both Jeff and Thomas to Enosi Life Sciences as we prepare for a period of growth and enhanced shareholder visibility,” said Dr. H. Michael Shepard, co-founder of Enosi Life Sciences. “As we continue the development of our novel therapies for cancer, autoimmune diseases, and inflammatory conditions, we are also focused on building an executive team that can help chart the course of the company moving forward. The additions of Jeff and Thomas strengthen our financial operations and provide leadership as we seek avenues to raise capital and eventually generate revenue.”

About Enosi Life Sciences
Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. The company was founded by world-renowned scientists Professor Sir Marc Feldmann, who discovered anti-tumor necrosis factor (anti-TNF) therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases (Lasker Award, 2003 ); and Dr. H. Michael Shepard, whose research in humanized antibodies created the first monoclonal antibody therapy targeting cancer oncogene encoded-proteins (Lasker award, 2019). Enosi Life Sciences combines Feldmann and Shepard’s expertise in cancer and autoimmune diseases with Executive Chairman Dr. James N. Woody’s unique combination of medical, scientific and management expertise to expand therapeutic options. To learn more about Enosi Life Sciences, visit www.enosi-life.com.

IR Contact
Tom Becker
VP Investor Relations
Investment@enositherapeutics.com
Enosi-Life Sciences Corp.
702-445-7038
www.enosi-life.com

Media Relations Contact
Matt Bretzius
FischTank PR
enosi@fischtankpr.com 

Group 3 Copy 2

James N. Woody

Executive Chairman

  • Jim brings more than 25 years of pharmaceutical research and management experience to Enosi.
  • In addition to his duties as a consultant to LVP, where he served as a General Partner for 14 years, Jim is currently Chairman of Viracta Therapeutics, a company focusing on unique therapies for virally induced cancers.  
  • He was the founding CEO of OncoMed Pharmaceuticals, a cancer therapeutic antibody company. He was the Board member for both ForteBio, and Protein Simple, both successfully acquired. Jim was formerly President and GM of Roche Bioscience (former Syntex) in Palo Alto, CA. 
  • Previously, Jim served as Chief Scientific Officer and Senior Vice President of R&D for Centocor. While at Centocor, Jim’s team developed the blockbuster drug Remicade. 
  • Jim served as a Navy Medical Officer, and was Head of the Navy Transplant Research Program. With his colleagues and with both Navy and Congressional support, founded the National Marrow Donor Program. 
  • He was promoted to Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War and was awarded the Marine Corps/US Navy Legion of Merit for his service. 
  • Jim served as Chairman of the Silicon Valley Leadership Group representing over 120 Silicon Valley Companies, is a board member of the Lucile Packard Children’s Hospital (Stanford).
  • Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. He was Professor of Pediatrics and Microbiology at Georgetown University School of Medicine 1982-1996. He has authored or co-authored over 140 publications.
Group 3 Copy

H. Michael Shepard, Ph.D.

CEO & Co-founder

  • Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics.
  • Best known for his invention of “Herceptin”/Trastuzumab, which has remained one of the most profitable platforms for Roche (>$7B USD).
  • Dr. Shepard is a highly-experienced and respected leader with many successful ventures in this field – working at Genentech (sold to Roche – $46.8 B USD), Canji, Inc. (bought by Scheirng-Plough) and Halozyme (now valued at $2.6B USD).
  • Widely acknowledged biomarker pioneer and recognized worldwide, Dr. Shepard has received the 2019 Albert Lasker Award and the Warren Alpert Prize, among many other professional accolades.

Enosi Team SirMarc Lasker Circle

Sir Marc Feldmann, M.D. Ph.D.

Director & Co-founder

  • Sir Marc Feldmann is a preeminent immunologist, and an Emeritus Professor at the University of Oxford.
  • With Sir Ravinder Maini, identified TNF as a target. Trials of Infliximab (Remicade) they led were successful, and prompted J&J’s $4.9B USD acquisition of Centocor.
  • Anti-TNF sales > $50B USD globally.
  • Professor Sir Marc Feldmann is a Fellow of the Royal Society , of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent.
  • He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, the Ernst Schering Award.